Chardan Capital Lowers Immatics Price Target to 25.00

IMTX Stock  USD 7.10  0.03  0.42%   
Slightly above 61% of Immatics' investor base is looking to short. The analysis of the overall investor sentiment regarding Immatics NV suggests that many traders are alarmed. Immatics' investing sentiment can be driven by a variety of factors including economic data, Immatics' earnings reports, geopolitical events, and overall market trends.
  
Immatics had its price objective lowered by Chardan Capital from 28.00 to 25.00 in a report released on Thursday, The Fly reports. The firm currently has a buy rating on the stock. Immatics Price Performance Shares of NASDAQIMTX opened at 6.74 on Thursday. Immatics has a 1-year low of 5.75 and

Read at thelincolnianonline.com
news
  

Immatics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Immatics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
58.2%
51.8%
51.7%
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Immatics Fundamental Analysis

We analyze Immatics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immatics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immatics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Profit Margin

Profit Margin Comparative Analysis

Immatics is currently under evaluation in profit margin category among its peers. Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.

Immatics NV Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immatics stock to make a market-neutral strategy. Peer analysis of Immatics could also be used in its relative valuation, which is a method of valuing Immatics by comparing valuation metrics with similar companies.

Peers

Immatics Related Equities

LYELLyell Immunopharma   7.61   
0%
100.0%
BCABBioatla   3.23   
0%
42.0%
MLYSMineralys Therapeutics,   2.01   
0%
26.0%
HRMYHarmony Biosciences   1.94   
0%
25.0%
AVTEAerovate Therapeutics   1.15   
0%
15.0%
CRNXCrinetics Pharmaceuticals   0.04   
1.0%
0%
FENCFennec Pharmaceuticals   0.32   
4.0%
0%
INBXInhibrx   0.74   
9.0%
0%
KRONKronos Bio   1.04   
13.0%
0%
SNDXSyndax Pharmaceuticals   1.39   
18.0%
0%
KROSKeros Therapeutics   1.43   
18.0%
0%
JANXJanux Therapeutics   1.73   
22.0%
0%
ALXOAlx Oncology   2.14   
28.0%
0%
MRUSMerus BV   2.25   
29.0%
0%
EWTXEdgewise Therapeutics   3.57   
46.0%
0%
REPLReplimune   4.77   
62.0%
0%

Additional Tools for Immatics Stock Analysis

When running Immatics' price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.
News Freq…Investor S…